ELICIA CURRIER: Open Payments
NPI 1457772576 · LAS CRUCES, NM. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$814 in 26 payments from 12 companies in 2025. Trend: 2023 $544 · 2024 $883 · 2025 $814
Food & beverage: $814
| Company | Payments | Amount |
|---|---|---|
| Travere Therapeutics, Inc. | 1 | $146 |
| Calliditas Therapeutics US Inc. | 3 | $117 |
| Alnylam Pharmaceuticals Inc. | 1 | $110 |
| AstraZeneca Pharmaceuticals LP | 5 | $93 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $79 |
| Amgen Inc. | 2 | $65 |
| Ardelyx, Inc. | 2 | $62 |
| SCPHARMACEUTICALS INC. | 2 | $43 |
| Novo Nordisk Inc | 2 | $32 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $30 |
Products named: Filspari, TARPEYO, AMVUTTRA, Kerendia, FARXIGA, KRYSTEXXA, IBSRELA, FUROSCIX.
Industry payments across NM — which companies pay providers there.
